Based on this evidence, the first studied ICIs in cervical cancer were the PD-1 inhibitors, that prevents the activation of the PD-1/PD-L1 inhibitory signal, by binding the PD-1 receptor on T cells, and thus blocking its interaction with PD-L1 and PD-L2 ligands, therefore preserving T cell proliferation and cytokine production [10]. Here, CD274 is linked to cervical cancer.